Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - Analysis of prognostic factors (EORTC-STBSG collaborative study)

European Journal of Surgical Oncology

Volumn 40, Issue 4, 2014, Pages 412-419

  Bauer, S ^a   Rutkowski, P ^b   Hohenberger, P ^c   Miceli, R ^d   Fumagalli, E ^d   Siedlecki, J A ^b   Nguyen, B P ^a   Kerst, M ^e   Fiore, M ^d   Nyckowski, P ^f   Hoiczyk, M ^a   Cats, A ^e   Casali, P G ^d   Treckmann, J ^a   Van Coevorden, F ^e   Gronchi, A ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Metastatic disease; Surgery; Survival

Indexed keywords

IMATINIB;

ABDOMINAL WALL HERNIA; ABSCESS; ADULT; AGED; ARTICLE; BILE LEAKAGE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; EXON; FEMALE; FOLLOW UP; GASTRIC DYSMOTILITY; GASTROINTESTINAL STROMAL TUMOR; HOSPITALIZATION; HUMAN; INTESTINE FISTULA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERITONEAL DISEASE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE ILEUS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REOPERATION; RETROSPECTIVE STUDY; STOMACH OBSTRUCTION; SURGICAL MORTALITY; VERY ELDERLY; YOUNG ADULT;

GASTROINTESTINAL STROMAL TUMOR; IMATINIB; METASTATIC DISEASE; SURGERY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; PATIENT SELECTION; PERITONEAL NEOPLASMS; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SELECTION BIAS; TREATMENT OUTCOME;

EID: 84895930458     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.12.020     Document Type: Article

References (14)

1. S. Hirota, K. Isozaki, and Y. Moriyama et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
2. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2006 70 83
3. H. Joensuu, M. Eriksson, and H.K. Sundby et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 2012 1265 1272
4. G.D. Demetri, M. Von Mehren, and C.D. Blanke et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
5. G. Demetri, J. Desai, and J.A. Fletcher et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) Proc Am Soc Clin Oncol 22 2004 3001
6. M.A. Choti, J.V. Sitzmann, and M.F. Tiburi et al. Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 2002 759 766
7. S. Bauer, J.T. Hartmann, and M. de Wit et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 2005 316 325
8. P. Rutkowski, P. Nyckowski, and U. Grzesiakowska et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST) Neoplasma 50 2003 438 442
9. C.P. Raut, M. Posner, and J. Desai et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2006 2325 2331
10. C. Mussi, U. Ronellenfitsch, and J. Jakob et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 21 2010 403 408
11. S. Durrleman, and R. Simon Flexible regression models with cubic splines Stat Med 8 1989 551 561
12. T.E. Finucane How gravely ill becomes dying: a key to end-of-life care JAMA 282 1999 1670 1672
13. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients J Clin Oncol 28 2010 1247 1253
14. C.D. Blanke, G.D. Demetri, and M. Von Mehren et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625